Results 1 to 10 of about 44,418 (298)

Hospitalization for Heart Failure Among Patients With Diabetes Mellitus and Reduced Kidney Function Treated With Metformin Versus Sulfonylureas: A Retrospective Cohort Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Metformin and sulfonylurea are commonly prescribed oral medications for type 2 diabetes mellitus. The association of metformin and sulfonylureas on heart failure outcomes in patients with reduced estimated glomerular filtration rate remains ...
Tadarro L. Richardson, Amber J. Hackstadt, Adriana M. Hung, Robert A. Greevy, Carlos G. Grijalva, Marie R. Griffin, Tom A. Elasy, Christianne L. Roumie   +7 more
doaj   +2 more sources

Revealing the role of increased SK3 expression in sulfonylurea resistance triggered by prolonged exposure [PDF]

Nutrition & Diabetes
Background Sulfonylureas have long been utilized in the management of type-2 diabetes mellitus (T2DM) due to their insulin-secretagogue properties. However, their clinical efficacy is hindered by the risk of severe hypoglycemia and secondary sulfonylurea
Jung Gyu Park, Minseok Kim, Sungje Yoo, Sun Wook Hwang, Jongsoo Mok, Joonghoon Park, Keon Wook Kang   +6 more
doaj   +2 more sources

Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications

Nigerian Journal of Medicine, 2017
INTRODUCTION: We sought to explore the current state of evidence on sulfonylurea therapy in type 2 diabetes mellitus (T2DM) and critically examine the recommendations of major practice guidelines,and the overall ramifications of the issues thereof in ...
Chiedozie Kenneth Ugwoke, Urban Slokar, Atsuhito Nakayama, Nejc Umek   +3 more
doaj   +2 more sources

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +3 more sources

Sulfonylurea action re‐revisited [PDF]

Journal of Diabetes Investigation, 2010
Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)‐sensitive K+ (KATP) channels in pancreatic β‐cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP‐GEFII) to Rap1 signaling, which promotes insulin ...
Seino, Susumu, Chang-Liang Zhang, Shibasaki, Tadao   +2 more
openaire   +3 more sources

Long-Term Seizure and Neurodevelopmental Outcomes of Three Children with Developmental Delay, Epilepsy, and Neonatal Diabetes (DEND) Syndrome after Early Initiation of Sulphonylurea [PDF]

Annals of Indian Academy of Neurology
Developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome, caused by de novo mutations in ABCC8/KCNJ11 genes encoding Adenosine Triphosphate (ATP)-sensitive potassium channels, is an unusual cause of infantile-onset developmental/epileptic ...
Neena Baby, Kollencheri P Vinayan, Praveen Pavithran, Kshitij Bansal, Nisha Bhavani, Yatheesha B Lokeshappa, Arun G Roy   +6 more
doaj   +2 more sources

Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population‐Based Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Commonly prescribed diabetic medications such as metformin and sulfonylurea may be associated with different arrhythmogenic risks. This study compared the risk of ventricular arrhythmia or sudden cardiac death between metformin and ...
Teddy Tai Loy Lee, Jeremy Man Ho Hui, Yan Hiu Athena Lee, Danish Iltaf Satti, Yuki Ka Ling Shum, Pias Tang Hoi Kiu, Abraham Ka Chung Wai, Tong Liu, Wing Tak Wong, Jeffrey Shi Kai Chan, Bernard Man Yung Cheung, Ian Chi Kei Wong, Shuk Han Cheng, Gary Tse   +13 more
doaj   +1 more source

Clinical features and sulfonylurea usage among outpatients with diabetes aged ≥90 years in an urban diabetes clinic in Tokyo

Journal of Diabetes Investigation, 2022
Aims/Introduction Aging of society is accelerating in many countries. The purpose of this study was to describe the clinical features and sulfonylurea usage among diabetes outpatients aged ≥90 years (nonagenarians). Materials and Methods This study was a
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Shoko Hamano, Masato Kasuga   +8 more
doaj   +1 more source

Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2018
Permanent neonatal diabetes mellitus is most commonly caused by mutations in the ATP-sensitive potassium channel (KATP) subunits. Prompt initiation of sulfonylurea treatment can improve glycemic control in children with KCNJ11 mutation.
Jong Seo Yoon, Kyu Jung Park, Young Bae Sohn, Hae Sang Lee, Jin Soon Hwang   +4 more
doaj   +1 more source

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundThere were a limited number of studies about β-cell function after insulin initiation in patients exposed to long durations of sulfonylurea treatment.
Yeoree Yang, Jeong-Ah Shin, Hae Kyung Yang, Seung-Hwan Lee, Seung-Hyun Ko, Yu-Bae Ahn, Kun-Ho Yoon, Jae-Hyoung Cho   +7 more
doaj   +1 more source